Stock comparison
Bausch Health Companies
Halozyme Therapeutics
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
BHC
Bausch Health Companies
Market cap
$2.04B
Sector
Healthcare
HALO
Halozyme Therapeutics
Market cap
$8.1B
Sector
Healthcare
Overall winner
Halozyme Therapeutics HALO
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | BHC | HALO | Winner |
|---|---|---|---|
| Warren Buffett | 50C | 79B | HALO |
| Benjamin Graham | 18F | 83A | HALO |
| Philip Fisher | 47D | 65B | HALO |
| Peter Lynch | 17F | 53D | HALO |
| Joel Greenblatt | 17F | 40D | HALO |
| Charlie Munger | 56D | 80C | HALO |
| Terry Smith | 49D | 84A | HALO |
Side-by-side metrics
| Metric | BHC | HALO |
|---|---|---|
| Market cap | $2.04B | $8.1B |
| P/E (TTM) | - | 24.0x |
| EV/EBIT | 9.7x | 10.2x |
| ROIC (TTM) | 11.59% | 23.65% |
| Gross margin | 61.67% | 81.24% |
| Net margin | -11.27% | 23.13% |
| Revenue CAGR 5y | 5.49% | 33.23% |
| EPS CAGR 5y | - | -1.98% |
| Debt / Equity | - | 1.0x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
BHC leads on
- Debt / Equity-vs 1.0x+109%
- P/E (TTM)-vs 24.0x+107%
- EV/EBIT9.7xvs 10.2x+5%
HALO leads on
- Net margin23.13%vs -11.27%+149%
- Revenue CAGR 5y33.23%vs 5.49%+83%
- Market cap$8.1Bvs $2.04B+75%
- ROIC (TTM)23.65%vs 11.59%+51%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.